Prudentia Sciences

Prudentia Sciences builds an AI-powered technology platform that supplies a scientific intelligence layer for life sciences dealmaking, serving pharmaceutical, biotechnology and investor communities. The company's technical work centres on artificial intelligence trained on drug development, scientific evidence synthesis and expert-developed frameworks, applied to a domain where decisions turn on clinical, commercial and regulatory evidence. The Prudentia Sciences Platform is described as AI-native. It combines expert-developed frameworks, AI trained on drug development and a unified evidence base to produce decision-ready outputs for asset assessment, risk identification and go/no-go decisions, as well as trade-off optimisation across time, cost, probability of success and revenue. The markets it addresses are large: the company cites more than $250 billion in life sciences business development, licensing and M&A activity annually, and more than $1 trillion in capital awaiting investment opportunities in the sector. The firm is headquartered in Cambridge, Massachusetts, and was founded by a team with expertise across medicine, technology and life sciences innovation. Its stated mission is to accelerate investment in breakthrough therapies. Investors include GV (Google Ventures), McKesson Ventures, Iaso Ventures, Virtue and SignalFire.

About

Markets

Similar companies